GlobeNewswire by notified

Nyxoah Reports First Quarter 2024 Financial and Operating Results



Nyxoah Reports First Quarter 2024 Financial and Operating Results
Announced DREAM U.S. pivotal study achieved primary endpoints
On track for FDA approval as early as end of 2024

Mont-Saint-Guibert, Belgium – May 14, 2024 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the first quarter of 2024.

Recent Financial and Operating Highlights

  • Reported the DREAM U.S. pivotal study achieved co-primary endpoints on an intent-to-treat (ITT) basis and demonstrated strong AHI reductions in supine and non-supine sleep positions.
  • The DREAM study achieved a median AHI reduction of 70.8%, a 12-month AHI responder rate, per the Sher criteria, of 63.5% (p=0.002) on an ITT basis and a 12-month ODI responder rate of 71.3% (p<0.001) on an ITT basis.
  • Preparing the fourth and final PMA module for submission this quarter.
  • Appointed Dr. Maurits S. Boon, MD as Chief Medical Officer.
  • Advanced patient access strategy through partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation (AAO-HNSF).
  • Achieved quarterly sales of €1.2 million, showing 170% growth vs Q1 2023.
  • Total cash position of €44.3 million at the end of the quarter.

“The DREAM U.S. study achieving its primary endpoints is a pivotal milestone for Nyxoah and further differentiates Genio as the only HGNS therapy to demonstrate strong efficacy in supine and non-supine OSA. With the DREAM data in hand, our U.S. launch preparations are focused on attracting commercial talent to set us up for success when we introduce Genio,” commented Olivier Taelman, Nyxoah Chief Executive Officer. “With continued European commercial traction, positive DREAM data and a highly differentiated, patient centric HGNS solution, I could not be more excited for Nyxoah’s future.”

First Quarter 2024 Results

(in thousands)

For the three months ended March 31, 
Revenue € 1,221€ 441
Cost of goods sold (455)(175)
Gross profit€ 766€ 266
Research and Development Expense (7,199)(6,157)
Selling, General and Administrative Expense (5,972)(5,551)
Other income/(expense) 19246
Operating loss for the period€ (12,213)€ (11,396)
Financial income 1 408625
Financial expense ( 991)( 958)
Loss for the period before taxes€ (11,796)€ (11,729)
Income taxes ( 110)( 182)
Loss for the period€ (11,906)€ (11,911)
Loss attributable to equity holders€ (11,906)€ (11,911)
Other comprehensive income/(loss)
Items that may not be subsequently reclassified to profit or loss (net of tax)
Currency translation differences 60(28)
Total comprehensive loss for the year, net of tax€ (11,846)€ (11,939)
Loss attributable to equity holders€ (11,846)€ (11,939)
Basic loss per share (in EUR) € (0.415)€ (0.460)
Diluted loss per share (in EUR) € (0.415)€ (0.460)


(in thousands)

As at
March 31
December 31 2023
Non-current assets
Property, plant and equipment€4,379€4,188
Intangible assets48,50146,608
Right of use assets3,5973,788
Deferred tax asset13456
Other long-term receivables1 3331,166
€ 57,944€ 55,806
Current assets
Trade receivables2,9712,758
Other receivables3,1493,212
Other current assets1,2321,318
Financial assets22,22536,138
Cash and cash equivalents22,07721,610
€ 55,072€ 68,351
Total assets€ 113,016€ 124,157
Capital and reserves
Share premium246,188246,127
Share based payment reserve8,4407,661
Other comprehensive income197137
Retained loss(172,555)(160,829)
Total equity attributable to shareholders€ 87,197€ 98,022
Non-current liabilities
Financial debt8,6168,373
Lease liability2,9333,116
Pension liability229
Deferred tax liability9
€ 11,844€ 11,692
Current liabilities
Financial debt346364
Lease liability852851
Trade payables7,3168,108
Current tax liability2,0911,988
Other payables3,3703,132
€ 13,975€ 14,443
Total liabilities€ 25,819€ 26,135
Total equity and liabilities€ 113,016€ 124,157

Revenue was €1.2 million for the first quarter ending March 31, 2024, compared to €441,000 for the first quarter ending March 31, 2023. The increase in revenue was attributable to the Company’s commercialization of the Genio® system, primarily in Germany.

Cost of Goods Sold

Cost of goods sold was €455,000 for the three months ending March 31, 2024, representing a gross profit of €0.8 million, or gross margin of 62.7%. This compares to total cost of goods sold of €175,000 in the first quarter of 2023, for a gross profit of €266,000, or gross margin of 60.3%.

Research and Development
For the first quarter ending March 31, 2024, research and development expenses were €7.2 million, versus €6.2 million for the first quarter ending March 31, 2023.

Operating Loss
Total operating loss for the first quarter ending March 31, 2024 was €12.2 million versus €11.4 million in the first quarter ending March 31, 2023. This was driven by the acceleration in the Company’s R&D spending, as well as ongoing commercial and clinical activities.

Cash Position
As of March 31, 2024, cash and financial assets totaled €44.3 million, compared to €57.7 million on December 31, 2023. Total cash burn was approximately €4.5 million per month during the first quarter 2024.

First Quarter 2024
Nyxoah’s financial report for the first quarter 2024, including details of the consolidated results, are available on the investor page of Nyxoah’s website (

Conference call and webcast presentation
A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q1 2024 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Nyxoah’s Q1 2024 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

David DeMartino, Chief Strategy Officer


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

The subscription period for the warrants of series TO7 starts today, May 20, 202420.5.2024 08:30:00 CEST | Press release

Today, May 20, 2024, marks the commencement of the exercise period for subscription of warrants of series TO7 in Terranet AB (publ) (”Terranet” or the” Company”). The exercise period for warrants of series TO7 runs up until and including June 3, 2024. Each warrant gives the right to subscribe for one (1) new share of series B in the Company to the price of SEK 0.073 per share. The invested amount must be rounded up to two decimal places. For the warrants not to expire without value, the owner must actively subscribe for new shares no later than June 3, 2024, alternatively sell their warrants no later than May 29, 2024. Please observe that certain nominees might close their application period earlier than June 3, 2024. The letter to holders of warrants of series TO7 is available on the Company's website Summarized terms for the warrants of series TO7: Subscription period: May 20, 2024 – June 3, 2024. Issue size: 182,664,660 warrants of series TO7, which entitles to subs

Teckning av aktier med stöd av teckningsoptioner av serie TO7 inleds idag, 20 maj 202420.5.2024 08:30:00 CEST | Pressemelding

Idag, den 20 maj 2024, inleds nyttjandeperioden för teckningsoptioner av serie TO7 i Terranet AB (publ) (”Terranet” eller ”Bolaget”). Nyttjandeperioden pågår till och med den 3 juni 2024. Varje teckningsoption av serie TO7 berättigar innehavaren till teckning av en (1) ny B-aktie i Bolaget till ett pris om 0,073 SEK per aktie. Investerat belopp avrundas uppåt till två decimaler. För att teckningsoptionerna inte ska förfalla utan värde krävs att innehavaren aktivt tecknar aktier senast den 3 juni 2024, alternativt säljer teckningsoptionerna senast den 29 maj 2024. Observera att vissa förvaltare kan stänga anmälningsperioden före den 3 juni 2024. Brev till teckningsoptionsinnehavare av serie TO7 finns att tillgå från Bolagets webbplats på Sammanfattade villkor för teckningsoptionerna av serie TO7: Teckningsperiod: 20 maj 2024 – 3 juni 2024. Emissionsvolym: 182 664 660 teckningsoptioner av serie TO7 berättigar till teckning av 182 664 660 B-aktier. Vid fullt nyttjande til


LEADING EDGE MATERIALS APPOINTS KURT BUDGE AS CHIEF EXECUTIVE OFFICER Vancouver, May 19, 2024 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) (FRA: 7FL) is pleased to announce the appointment of Mr. Kurt Budge as Chief Executive Officer. Chairman Lars-Eric Johansson noted: “The Board is very happy to welcome Kurt to the Company in the role as Chief Executive Officer given his considerable experience leading junior mining companies and especially his knowledge of working in Sweden. The Rare Earth Elements at Norra Kärr makes the project an obvious candidate as a Strategic Project as defined by the EU Critical Raw Materials Act and the Company is focused on applying for this designation. The Exploitation Concession application and environmental work for Norra Kärr are also key priorities. The Company has other Strategic Raw Materials in its portfolio, Natural Graphite at the established mine at Woxna in Swe

Inside Information: Manu Skyttä starts as the President and CEO of Aspocomp Group Plc20.5.2024 08:00:00 CEST | Press release

Aspocomp Group Plc, Inside Information, May 20, 2024, at 9:00 a.m. (Finnish time) Mr. Manu Skyttä, MSc, Aeronautical Engineering, who was appointed as the new President and CEO of Aspocomp Group Plc in February, starts his position today. The Company issued a release on the appointment of Manu Skyttä on February 15, 2024. “We are pleased with the appointment of Mr. Manu Skyttä,” says Ms. Päivi Marttila, Chairman of the Board of Directors. “Manu’s energy and his passion for change and growth, together with his wide experience from different business functions, give him strong competence to develop Aspocomp into the next phase,” adds Päivi Marttila. For further information, please contact Päivi Marttila, Chairman of the Board of Directors, tel. +358 400 285 358. ASPOCOMP GROUP PLC Päivi Marttila Chairman of the Board of Directors Aspocomp – heart of your technology A printed circuit board (PCB) is used for electrical interconnection and as a component assembly platform i

Hexagon Purus and Hino Trucks Introduce Tern: A Pioneering Electric Heavy-Duty Truck20.5.2024 07:00:00 CEST | Press release

Las Vegas, NV, May 20, 2024 – Today at the Advanced Clean Transportation (ACT) Expo, Hexagon Purus in partnership with Hino Trucks, proudly announces the launch of Tern, a dedicated zero-emission truck brand along with their inaugural vehicle model, the RC8, a groundbreaking battery electric Class 8 tractor tailored for the U.S. market. This innovative semi-tractor leverages Hexagon Purus' years of development of zero-emission drivetrains for heavy-duty trucks and represents a driver-preferred option for fleets that are electrifying practical routes. A product of the new long-term agreement between Hexagon Purus and Hino Trucks, valued at up to approximately $2 billion, Tern is designed to deliver a seamless transition to electrification for the U.S. commercial vehicle sector. Manufactured in Hexagon Purus' new facility in Dallas, Texas, the Tern RC8 is scheduled for serial production in late 2024. Built on Hino's proven XL Series 4x2 chassis and equipped with Hexagon Purus' cutting-ed

HiddenA line styled icon from Orion Icon Library.Eye